Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-α Therapy
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
This study investigated the expression of T-cell immunoglobulin- and mucin-domain-containing
molecule 3 (TIM-3) in the colonic mucosa and/or the peripheral blood of children with Crohn's
disease during anti TNF-α (infliximab) therapy.